# Droperidol Intravenous for Adults

## Who can administer

Administration RESTRICTED - see Appendix 1

## Important information

- Contraindicated in patients with known or suspected prolonged **QT interval**
- Avoid use with **medications which also cause QTc prolongation**
- Cardiovascular monitoring required (see monitoring requirements below)

## Available preparations

Droperidol (Panpharma) 2.5mg per 1mL ampoule (unlicensed)

## Reconstitution

Already in solution

**Draw up using a 5 micron filter needle**

## Methods of intravenous administration

**Slow intravenous injection**

- Administer over at least 3 minutes [ref 1]

## Dose in adults

**Prevention and treatment of post-operative nausea and vomiting (PONV)**

- Adults: 0.625 to 1.25mg (see also further information)
- Elderly: maximum 0.625mg
- May be repeated every six hours as required
- **Renal/hepatic impairment: maximum 0.625mg (caution advised** in renal and hepatic impairment)
- **Administration** of droperidol is **recommended 30 minutes before the anticipated end of surgery**

## Monitoring

- Continuous pulse oximetry should be performed in patients with known or suspected risk of ventricular arrhythmia and should continue for 30 minutes following single intravenous administration [(ref 1)]
- ECG monitoring if cardiovascular risk factors[(ref 1)]
- Monitor blood pressure and heart rate[(ref 1)]

## Further information

- The manufacturers suggest that droperidol may be added to PCA. However, this is not practice within GUH. See SPC for further details

## Storage

Store below $25^{0}$C

## References

Droperidol (Aguettant) downloaded March 2025

1: Medusa http://medusa.wales.nhs.uk/ accessed online 23rd Feb 2023

## Therapeutic classification

Anti-emetic, Butyrophenone neuroleptic

BNF
CNS